Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2003

View Archived Issues

BMS researchers describe two series of antidiabetic compounds

Novel immunosuppressants covered by Sankyo patent

Potent, selective PDE5 inhibitors prepared and tested at Lilly Icos

Agouron discovers novel nonpeptide GnRH antagonists

GSK scientists describe the discovery of novel anti-HCV agents

New antibacterial PDF inhibitors in early development at GSK

Pierre Fabre presents novel inhibitors of protein prenyltransferases

New data on cantuzumab mertansine in tumors expressing the CanAg antigen

Approval recommended for Enteryx in GERD

E.U. approves Taxotere in combination with cisplatin for first-line NSCLC treatment

CYC-202 enters phase IIa trials in breast and lung cancers

LidoPAIN IND cleared

ANDROMEDA trial discontinued due to safety concerns

Dosing begins in phase II trial of FM-VP4

Medarex and Abbott enter therapeutic antibody collaboration

Kiadis and U. of Bristol form neuropathic pain alliance

Applied Molecular Evolution completes preclinical validation of lead candidates

Potential use of nicotinic receptor antagonists as mood stabilizers in affective disorders

Hepacare marketing authorization withdrawn in E.U.

Disappointing phase II results reported for ReN-1869

HMR-1556 potently and selectively blocks the slowly activating delayed rectifier K+ current

Antimalarial activity of cyproheptadine involves inhibition of heme polymerization

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...